Cynomolgus Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)
Cat. No. IT7-C52W4
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Integrin alpha 4 beta 7 | Cynomolgus Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified) | Cynomolgus | HEK293 | MALSSDS-PAGE | $475.00 100ug | |||
| Integrin alpha 4 beta 7 | Avitag IT7-C82W3 | Biotinylated Cynomolgus Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $160.00 25ug | |
| Integrin alpha 4 beta 7 | Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free, low endotoxin (Mass Spec & MALS & SPR verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $535.00 100ug | ||
| Integrin alpha 4 beta 7 | Avitag IT7-H82W4 | Biotinylated Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Colitis, Ulcerative; Crohn Disease; Pouchitis | Details |
| Vedolizumab Biosimilar (Intas Pharmaceuticals) | INTP-53; INTP53 | Phase 3 Clinical | Intas Pharmaceuticals Ltd | Colitis, Ulcerative | Details |
| Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | Details |
| LY-4268989 | MORF-057; LY-4268989; LY4268989 | Phase 2 Clinical | Morphic Therapeutic Inc | Colitis, Ulcerative; Crohn Disease | Details |
| EA-1080 | EA-1080; NSHO-101 | Phase 2 Clinical | Ea Pharma | Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases | Details |
| PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
| Emvistegrast | GS-1427 | Phase 2 Clinical | Gilead Sciences Sl | Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| ABBV-466 | Phase 2 Clinical | Abbvie Inc | Crohn Disease | Details | |
| SPY-001 | SPY001; SPY-001; PR-011; PR011; SPY001-001 | Phase 2 Clinical | Paragon Therapeutics Inc | Colitis; Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| Trosunilimab | ABBV-382 | Phase 2 Clinical | Abbvie Inc | Crohn Disease; HIV Infections | Details |
| PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
| NSHO-102 | NSHO-102 | Phase 1 Clinical | Ensho Therapeutics Inc | Inflammatory Bowel Diseases | Details |
| Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 1 Clinical | Alvotech Swiss Ag | Colitis, Ulcerative; Immune System Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Carcinoma, Non-Small-Cell Lung; Celiac Disease; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Crohn Disease; Gastritis; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Inflammatory Bowel Diseases; Melanoma; Neoplasms; Pediatric Crohn's disease; Pediatric ulcerative colitis; Pouchitis; Solid tumours; Urogenital Neoplasms | Details |
| Natalizumab biosimilar (Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body | Details |